doi: 10.1002/1097-0142(197508)36:2<471::aid-cncr2820360225>3.0.co;2-4.
Growth rate of pulmonary metastases in human sarcomas
- PMID: 1057449
- DOI: 10.1002/1097-0142(197508)36:2<471::aid-cncr2820360225>3.0.co;2-4
Item in Clipboard
Growth rate of pulmonary metastases in human sarcomas
Cancer.
1975 Aug.
Abstract
The growth rate of spherical pulmonary metastases was studied in 15 patients with osseous and soft tissue sarcoma. The median volume doubling time (Dt) was 25 days. The time from diagnosis of the primary tumor to occurrence of pulmonary metastases correlated directly with the length of Dt. No correlation between Dt and tumor histology was observed. The effect of therapy on the tumor growth curve was studied in 1 patient. The therapeutic implications derived from the quantitative evaluation of tumor growth rate are discussed.
Similar articles
-
Treatment of pulmonary metastatic disease with radiation therapy and adjuvant actinomycin D. Preliminary observations.Cancer. 1969 Oct;24(4):719-23. doi: 10.1002/1097-0142(196910)24:4<719::aid-cncr2820240409>3.0.co;2-a. Cancer. 1969. PMID: 4309693 No abstract available.
-
Lymphatic dissemination of bone and soft tissue sarcomas: a lymphographic investigation.Acta Radiol Suppl. 1976;349:1-84. Acta Radiol Suppl. 1976. PMID: 206099 Review.
-
A comparative clinical trial evaluating the combination of adriamycin, DTIC, and vincristine, the combination of actinomycin D, cyclophosphamide, and vincristine, and a single agent, methyl-CCNU, in advanced sarcomas.Cancer Treat Rep. 1976 Sep;60(9):1385-7. Cancer Treat Rep. 1976. PMID: 189922 Clinical Trial. No abstract available.
-
Chemotherapy in complex treatment of bone and soft tissue sarcomas.Oncology. 1980;37 Suppl 1:97-103. doi: 10.1159/000225505. Oncology. 1980. PMID: 7005794 No abstract available.
-
The value of adjuvant chemotherapy in the management of sarcomas in children.Cancer. 1985 May 1;55(9 Suppl):2184-97. doi: 10.1002/1097-0142(19850501)55:9+<2184::aid-cncr2820551422>3.0.co;2-n. Cancer. 1985. PMID: 3884137 Review.
Cited by
-
Measurement of growth rate of lung metastases in 21 patients with bone or soft-tissue sarcoma.Br J Cancer. 1993 Aug;68(2):414-7. doi: 10.1038/bjc.1993.351. Br J Cancer. 1993. PMID: 8347499 Free PMC article.
-
Small cell anaplastic carcinoma of the lung. A review of growth characteristics and implications for chemotherapy.Cancer Chemother Pharmacol. 1982;9(1):1-5. doi: 10.1007/BF00296751. Cancer Chemother Pharmacol. 1982. PMID: 6291797 Review.
-
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).Front Oncol. 2019 Mar 11;9:132. doi: 10.3389/fonc.2019.00132. eCollection 2019. Front Oncol. 2019. PMID: 30915273 Free PMC article.
-
Rapidly growing intrathoracic extraskeletal Ewing's sarcoma.Interact Cardiovasc Thorac Surg. 2012 Jan;14(1):117-9. doi: 10.1093/icvts/ivr023. Epub 2011 Nov 15. Interact Cardiovasc Thorac Surg. 2012. PMID: 22108933 Free PMC article.
-
Clinical impact of the tumor volume doubling time on sarcoma patients with lung metastases.Clin Exp Metastasis. 2011 Dec;28(8):819-25. doi: 10.1007/s10585-011-9413-9. Epub 2011 Jul 30. Clin Exp Metastasis. 2011. PMID: 21805254